Global Oral Antibiotics Market to Grow at a CAGR of 2.50% During the Forecast Period of 2026-2035, Aided by the Robust Healthcare Sector

North America accounts for a considerable share of the oral antibiotics industry owing to the robust healthcare sector in the region. The wide accessibility to quality healthcare in the United States and Canada is surging the demand for oral antibiotics to treat various health-related issues, driving the market growth. In addition, the increasing research and development (R&D) activities to develop innovative and advanced oral antibiotics is driving the market growth. The Asia Pacific region is witnessing robust growth owing to the rising manufacturing of oral antibiotics in countries like India and China, among others. Furthermore, as the prevalence of infectious issues such as tuberculosis and influenza is surging, the market for oral antibiotics is growing significantly. Moreover, the increasing focus to address the emerging issue of antibiotic resistance is projected to provide lucrative growth opportunities to the market growth in the forecast period.

GlaxoSmithKline plc (NYSE: GSK), one of the leading companies in the market, announced in October 2019 that it had initiated a Phase III clinical program to investigate the efficacy of gepotidacin in patients with urogenital gonorrhoea (GC) and uncomplicated urinary tract infections (UTI). The phase III program comprised two studies- to compare gepotidacin to ceftriaxone and azithromycin in urogenital gonorrhoea and compare gepotidacin to nitrofurantoin for urinary tract infection. The novel oral antibiotic is developed with a public-private relationship with the company and the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) of the United States. The clinical trial of oral antibiotics is an important step to support the development of various antibiotics to fight bioterrorism and antibiotic resistance. As a result, such clinical trials are augmenting the market's growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Class, Application, Drug Origin, Spectrum of Activity, Drug Type, and Region:

• The market, based on class, can be divided into beta-lactam and beta-lactamase inhibitors, quinolones, and macrolides, among others.
• Based on application, the industry can be divided into community-acquired respiratory tract infections (CARTIs), urinary tract infections (UTIs), and dental, among others.
• The major drug origins of oral antibiotics include natural, semisynthetic, and synthetic.
• On the basis of the spectrum of activity, the market is segmented into broad-spectrum antibiotics and mid/narrow-spectrum antibiotics.
• Based on drug type, the market is bifurcated into branded and generics.
• The regional markets for oral antibiotics include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

Key Findings of the Report:

• The extensive use of oral antibiotics to treat infectious diseases like tuberculosis and influenza is augmenting the market growth.
• The market is being propelled by the growing prevalence of urinary tract infections (UTIs), which, in turn, is surging the demand for oral antibiotics.
• The increasing research activities to develop new oral antibiotics due to the growing focus on global health threats, in the wake of the COVID-19 crisis, is driving the market's growth.
• The growing investments in developing innovative oral antibiotics by both governments and private players are bolstering the industry growth.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for oral antibiotics for the periods (2019-2025) and (2026-2035).
• The report also offers the historical (2019-2025) and forecast (2026-2035) markets for the classes, applications, drug origins, spectrum of activities, drug types, and major regions of oral antibiotics.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

Top Players

• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc.
• AstraZeneca plc.
• Roche Holding AG
• Bayer AG
• Johnson & Johnson
• Sanofi
• Alkem Laboratories Ltd.
• Cipla Ltd.
• Abbott Laboratories
• Lupin
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium-sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790